Additional Technology. It is anticipated that Licensors may from time to time develop additional technology. In the event Licensor desire to market, distribute, or otherwise exploit any additional technology relating to the remediation of toxic flue gases that is not included within the above defined Technology (the "Additional Technology") in the World-wide Territory of Licensee, Licensors shall provide Licensee with a written notice (the "Initial Notice") setting forth full details concerning the Additional Technology, and Licensee shall have the exclusive right and option to have the Additional Technology made subject to this Agreement at any time during a period of 90 days following the date such Initial Notice is given. Licensee can exercise such option by delivery of a notice of its intent to do so within the option period. If Licensee does not exercise its option within the prescribed period, Licensor shall be entitled to enter into any agreement respecting the Additional Technology within the World-wide Territory of Licensee with any other entity. If Licensee is granted rights to Additional Technology, such rights shall be subject to all the terms and provisions of this Agreement and the Additional Technology shall be treated as Technology under this Agreement.
Additional Technology. During the Development Program Term, if SB or Aphton believe that technology related to the subject matter of the Development Program that is controlled by a Third Person, which may include new lmmunogens, adjuvants and/or Blocking Patents ("Additional Technology") would be valuable or necessary to the Development Program in the Field hereunder Aphton or SB as appropriate shall present such Additional Technology to the Steering Committee along with a written report. The Steering Committee shall then determine, except for Blocking Patents which shall be at SB's sole discretion subject to other provisions contained herein, whether licenses to, and/or acquisitions of, such Additional ------------------------ * The redacted portions of this document have been omitted pursuant to a request for confidential treatment and such redacted portions have been filed separately with the Securities and Exchange Commission. Technology should be made, and SB shall approach and negotiate the terms of any agreement(s) with any Third Person including, without limitation payments for sponsored research. No such Third Person license and/or acquisition shall be effective with respect to SB unless and until SB has specifically agreed in writing to abide by the applicable terms and conditions of any such license and/or acquisition.
Additional Technology. Any Invention that is [CONFIDENTIAL TREATMENT REQUESTED]/*/ at any time on or before [CONFIDENTIAL TREATMENT REQUESTED]/*/, shall automatically be included within the definition of “Technology” for purposes of this Agreement (and any patents or patent applications relating to such Inventions shall automatically be added to Schedule 1). EXACT shall promptly notify LABCORP in writing of all such Inventions. In addition, EXACT shall provide notice to LABCORP of any Invention that is [CONFIDENTIAL TREATMENT REQUESTED]/*/ at any time after [CONFIDENTIAL TREATMENT REQUESTED]/*/ during the Term of this Agreement but prior to [CONFIDENTIAL TREATMENT REQUESTED]/*/ (an “Applicable EXACT Invention”). Upon delivery of such notice and for a period of [CONFIDENTIAL TREATMENT REQUESTED]/*/ days thereafter, EXACT agrees to [CONFIDENTIAL TREATMENT REQUESTED]/*/. Notwithstanding the foregoing, EXACT reserves the right to [CONFIDENTIAL TREATMENT REQUESTED]/*/, in its sole discretion. However, in the event that[CONFIDENTIAL TREATMENT REQUESTED]/*/, and EXACT [CONFIDENTIAL TREATMENT REQUESTED]/*/, then in each such case EXACT shall [CONFIDENTIAL TREATMENT REQUESTED]/*/.
Additional Technology. 14 4.6 Internal Corixa Gene Discovery Research ..........................14 4.7 Limitations ......................................................14 ARTICLE 5
Additional Technology. During the Research Term, if either party believes that technology related to the subject matter of the Research that is Controlled by such party or a Third Party ("Additional Technology") would be valuable or necessary to the Research in the Field hereunder, such party shall present such technology, along with a written report with respect thereto, to the Research Management Committee. The Research Management Committee shall then determine whether licenses to, and/or acquisitions of, such Additional Technology shall be made, the party that shall approach and negotiate with any Third Parties and the terms of any agreements with any Third Parties, including, without limitation, payments for sponsored research. No such Third Party license and/or acquisition shall be effective with respect to the other party unless and until such other party has specifically agreed in writing to abide by the applicable terms and conditions of any such license and/or acquisition (other than payment terms, which are provided for in Sections 6.2 and 7.2 below). It is understood and agreed that with respect to all Additional Technology, Corixa's rights shall be limited to the Corixa Exclusive Field and GenQuest's rights shall be limited to the GenQuest Exclusive Field. Notwithstanding the foregoing, this Section 4.5 shall not be deemed to preclude either party from acquiring Additional Technology.
Additional Technology. It is expressly understood that GTE shall, at the request of PRTC, make available for sale to PRTC and its Affiliates such additional technology and systems that PRTC deems necessary to accomplish the objectives set forth in this Agreement and that GTE or GITI, if necessary, by license or assignment to GTE from GITI, is capable of providing subject to the provisions of the Shareholders Agreement.
Additional Technology. If Solae identifies any additional Solae Technology that may be relevant or useful for the research purposes under this Agreement, Senomyx may request a license of the relevant Solae Technology and Solae may in its reasonable discretion grant a license of the Solae Technology. Where Solae consents to a license in this Section 8.4, Solae will grant a fully paid, non-exclusive, non-transferable license to use the relevant Solae Technology for research purposes. For the avoidance of doubt this license will not include the right to sublicense unless Solae gives its consent, which may be withheld for any reason.
Additional Technology. In the event that either Licensor or any of their respective Affiliates owns or controls (including under license with a right to grant sublicenses thereunder) any technology relating to (a) the elimination or excretion of waste nitrogen which is not licensed hereunder (“Related Technology”), or (b) the treatment of conditions that relate to other waste nitrogen disorders in respect of which no rights are licensed hereunder (“Complementary Technology” and, together with Related Technology, “New Technology”), Licensee shall have the right of first offer and last refusal to license the New Technology from such Licensor on the following terms: Upon written request of Licensee, or in any event prior to offering rights to any New Technology to any Third Party, the applicable Licensor shall offer Licensee the right to obtain a license to such New Technology, by delivering to Licensee all data available to Licensors relating to the New Technology and its safety and efficacy together with a proposal for commercial terms, if available (the “Proposal”). Licensee shall have *** following receipt of the Proposal (the “Indication of Interest Notice Period”) to *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. indicate whether or not it is interested in exercising an option to acquire a license under the New Technology which is the subject of the Proposal. If Licensee delivers written notice to Licensors stating that it wishes to consider exercising an option in respect of such New Technology (an “Indication of Interest”), then for a period of *** after receipt by the applicable Licensor of the Indication of Interest (the “Exclusive Negotiation Period”), the applicable Licensor shall negotiate in good faith exclusively with Licensee concerning the terms and conditions of a license in respect of the New Technology, and during the Exclusive Negotiation Period, the applicable Licensor shall take no other action in connection with the possible commercialization of the New technology. The parties understand that, except as to financial terms, any license in respect of the New Technology shall contain terms and conditions substantially similar to those contained in this Agreement. In the event that (i) Licensee fails to deliver an Indication of Interest within the Ind...
Additional Technology. Startek agrees that it has the necessary technology and staffing capabilities to meet the requirements herein as of the Effective Date of this SOW. Requests for additional hardware and software shall be subject to the Change Management section of the MSA.
Additional Technology. BioWa agrees to make available to MedImmune a license to any improved or additional technology developed by BioWa and directly related to Potelligent Cells that is not licensed to MedImmune under this Agreement. Such additional license shall be on terms which are commercially reasonable, similar to the terms of this Agreement and acceptable to both parties.
